Paul Tudor Jones’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Paul Tudor Jones’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,726	Closed	-$46K	–	1363
2017 Q2	$46K	Buy	4,726 +1,445	+44%	+$29.5K	﹤0.01%	984
2017 Q1	$80K	Sell	3,281 -2,465	-43%	-$61.7K	﹤0.01%	1320
2016 Q4	$184K	Buy	+5,746	New	+$245K	﹤0.01%	1242
2016 Q3	–	Sell	-1,449	Closed	-$61K	–	1876
2016 Q2	$61K	Sell	1,449 -813	-36%	-$44.3K	﹤0.01%	1544
2016 Q1	$149K	Buy	+2,262	New	+$118K	﹤0.01%	1560
2015 Q1	–	Sell	-1,550	Closed	-$138K	–	1722
2014 Q4	$138K	Buy	+1,550	New	+$113K	﹤0.01%	1341
2014 Q3	–	Sell	-1,731	Closed	-$99K	–	1568
2014 Q2	$99K	Buy	+1,731	New	+$87.9K	﹤0.01%	1103

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Paul Tudor Jones's MACK Position: Q3 2017 in Review

Paul Tudor Jones sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 4,726 shares — an estimated $46K sold.

Paul Tudor Jones first reported a position in MACK in Q2 2014 and held it in 7 quarters. The position peaked at $184K in Q4 2016. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Paul Tudor Jones reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Paul Tudor Jones sold 4,726 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $46K.
Paul Tudor Jones first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 7 quarters.
Paul Tudor Jones's Merrimack Pharmaceuticals, Inc. position peaked at $184K in Q4 2016.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Tudor Investment Corp's 13F filing for Q3 2017, filed 14 Nov 2017.